Exdensur Approved by US FDA for the Treatment of Severe Asthma
December 17, 2025
December 17, 2025
LONDON, England, Dec. 17 (TNSjou) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 16, 2025:
* * *
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
* Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype
* Approval based on SWIFT trials showing significantly low . . .
* * *
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
* Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype
* Approval based on SWIFT trials showing significantly low . . .